Skeletal Events and the Treatment of Men with Advanced Prostate Cancer

Many of our doctors are constantly vigilant about our developing skeletal related issues.   Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of skeletal related event complications, however neither of these drugs improve survival nor delay mortality. They both are beneficial and have an important role in delaying the complications of bone metastases in men with metastatic castrate resistant prostate cancer (mCRPC). The two new “super” ADT drugs [...]

It Maybe Time To Change The Dosing Schedule Of Zoledronic Acid To Every 12 Weeks

In a presentation at the ASCO Annual Meeting,  Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included 1,822 patients (with three different diseases including Prostate Cancer, breast cancer and multiple myeloma) who were randomly assigned to receive zoledronic acid every 12 weeks or every 4 weeks for 2 years. The primary endpoint was incidence of developing any skeletal-related event (SRE). One thousand [...]

Make Sure You Receive the Correct IV Treatment, Injection and Dosage

It is vital that you take an active role in making sure that you are going to receive the correct IV treatment and injections. Mistakes do happen, protect yourself. Make sure that you personally double check to confirm you're receiving the correct treatment. Don't sit back and rely on another person, errors do occur and you will be the one to suffer. 1. When you see your oncologist ask for a list of the drugs you will be receiving at your next infusion. Bring this list with you to the infusion center. 2. At the infusion center the certified oncology [...]

Clinical Trial Evaluates Hormone Therapy With And Without Zoledronic Acid In Men With Prostate Cancer And Bone Metastases Who Are Treatment-Naïve

Zoledronic acid (ZA) is considered the standard of care to prevent skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases. The question that still remains is when to start the ZA. In a phase III clinical trial a total of 227 men with hormonal treatment-naïve prostate cancer and bone metastases were randomly assigned in a 1:1 ratio to receive zoledronic acid along with ADT (LH-RH analogue + bicalutamide) or ADT alone. After a median follow-up of 41.1 months it was found that in men with hormonal treatment naïve prostate cancer with bone metastases, concurrent use of ZA [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー